Where Will Smith & Nephew plc (SNN) Stock Go Next After It Is Down 1.53% in a Week?

Overall market sentiment has been high on Smith & Nephew plc (SNN) stock lately. SNN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Smith & Nephew plc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SNN!

See Full SNN Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With SNN Stock Today?

Smith & Nephew plc (SNN) stock is down -2.51% while the S&P 500 is up 0.09% as of 10:06 AM on Thursday, Mar 28. SNN is down -$0.66 from the previous closing price of $26.34 on volume of 269,780 shares. Over the past year the S&P 500 has gained 32.29% while SNN is down -7.66%. SNN earned $0.60 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 42.62. To see InvestorsObserver's Sentiment Score for Smith & Nephew plc click here.

More About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder. Click Here to get the full Stock Report for Smith & Nephew plc stock.